1 | clinical team but also | | | | | | | 5 | 0.70% |
2 | new immunotherapies require not | | | | | | | 4 | 0.56% |
3 | require not only an | | | | | | | 3 | 0.42% |
4 | focused treatment contact us | | | | | | | 3 | 0.42% |
5 | immunotherapies require not only | | | | | | | 3 | 0.42% |
6 | experienced clinical team but | | | | | | | 3 | 0.42% |
7 | team but also laboratory | | | | | | | 3 | 0.42% |
8 | but also laboratory support | | | | | | | 3 | 0.42% |
9 | also laboratory support and | | | | | | | 3 | 0.42% |
10 | to offer the most | | | | | | | 3 | 0.42% |
11 | unavailable to most community | | | | | | 3 | 0.42% |
12 | to most community practices | | | | | | 3 | 0.42% |
13 | us focused treatment contact | | | | | | | 3 | 0.42% |
14 | why us focused treatment | | | | | | | 3 | 0.42% |
15 | mission our goal why | | | | | | | 3 | 0.42% |
16 | goal why us focused | | | | | | | 3 | 0.42% |
17 | and followup many of | | | | | | | 2 | 0.28% |
18 | followup many of these | | | | | | | 2 | 0.28% |
19 | oncologists to focus more | | | | | | | 2 | 0.28% |
20 | admitting hospitals to allow | | | | | | | 2 | 0.28% |
21 | subject to risk evaluation | | | | | | | 2 | 0.28% |
22 | to risk evaluation and | | | | | | | 2 | 0.28% |
23 | risk evaluation and mitigation | | | | | | | 2 | 0.28% |
24 | evaluation and mitigation strategies | | | | | | | 2 | 0.28% |
25 | multiple sites including potential | | | | | | | 2 | 0.28% |
26 | across multiple sites including | | | | | | | 2 | 0.28% |
27 | resourceintensive for many practices | | | | | | | 2 | 0.28% |
28 | additional planning education supervision | | | | | | | 2 | 0.28% |
29 | integrates these administration and | | | | | | | 2 | 0.28% |
30 | planning education supervision and | | | | | | | 2 | 0.28% |
31 | education supervision and data | | | | | | | 2 | 0.28% |
32 | seamlessly integrates these administration | | | | | | | 2 | 0.28% |
33 | patient monitoring and followup | | | | | | | 2 | 0.28% |
34 | programs are frequently administered | | | | | | | 2 | 0.28% |
35 | are frequently administered across | | | | | | | 2 | 0.28% |
36 | frequently administered across multiple | | | | | | | 2 | 0.28% |
37 | which can be resourceintensive | | | | | | | 2 | 0.28% |
38 | can be resourceintensive for | | | | | | | 2 | 0.28% |
39 | be resourceintensive for many | | | | | | | 2 | 0.28% |
40 | monitoring and followup many | | | | | | | 2 | 0.28% |